HR 2407/S 2085 The Medicare Multi-Cancer Early Detection Screening Coverage Act; Appropriate payment and coverage criteria for certain advanced diagnostic tests
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing; Use of real-world evidence in clinical trials and FDA review; Cancer Moonshot; FDA proposed regulation to provide oversight of diagnostic lab tests (FDA-2023-N-2177)
Providing an appropriate regulatory model for advanced genomic cancer testing (FDA-2023-2177), Artificial Intelligence proposals
Duration: September 19, 2017
to
present
General Issues: Medicare/Medicaid , Medical/Disease Research/Clinical Labs , Health Issues , Copyright/Patent/Trademark
Spending: about $1,080,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2017: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), White House Office, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Justice - Dept of (DOJ)
Related Foreign Entities:
Caris Life Sciences LTD (Grand Cayman, CAY); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Amy Jensen Cunniffe Special Assistant to the President for Legislative Affairs (2003-2005); Assistant to the Speaker for Policy (1999-2001)
Assistant to the Speaker for Policy (1999-2001), Special Assistant to the President for Legislative Affairs (2003-2005)
Special Assistant to the President for Legislative Affairs; Assistant to the Speaker for Policy; Legislative Assistant; Policy Analyst
Special Assistant to the Speaker for Policy; Special Assistant to the President for Legislative Affairs; Policy Analyst; Legislative Assistant
Sarah Egge Legislative Assistant, Sen. Bob Kerrey (1998-2000); Senior Budget Committee Analyst (2001-2012); Deputy Staff Director, Joint Select Committee on Deficit Reduction (Fall 2011)
Legislative Assistant; Senior Budget Analyst; Deputy Staff Director, Joint Select Committee on Deficit Reduction
Legislative Assistant to Senator Bob Kerrey (1998-2000); Senior Budget Analyst for Democratic Staff of the Senate Budget Committee (2001-2012); Deputy Staff Director, Joint Select Committee on Deficit Reduction (Fall 2011)
Legislative Assistant to Senator Bob Kerrey; Senior Budget Analyst for Democratic staff of the Senate Budget Committee (Sen. Kent Conrad); Deputy Staff Director, Joint Select Committee on Deficit Reduction
Legislative Assistant to Senator Bob Kerrey (1998-2000); Senior Budget Analyst for Democratic Staff of the Senate Budget Committee (2001-2012); Deputy Staff Director\, Joint Select Committee on Deficit Reduction (Fall 2011)
Amy Jensen Special Assistant to the President for Legislative Affairs; Assistant to the Speaker for Policy; Legislative Assistant; Policy Analyst
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on April 22.
Original Filing: 301575275.xml
Lobbying Issues
HR 2407/S 2085 The Medicare Multi-Cancer Early Detection Screening Coverage Act; Appropriate payment and coverage criteria for certain advanced diagnostic tests
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing; Use of real-world evidence in clinical trials and FDA review; Cancer Moonshot; FDA proposed regulation to provide oversight of diagnostic lab tests (FDA-2023-N-2177)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Providing an appropriate regulatory model for advanced genomic cancer testing (FDA-2023-2177), Artificial Intelligence proposals
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on Jan. 22.
Original Filing: 301539152.xml
Lobbying Issues
HR 2407/S 2085 The Medicare Multi-Cancer Early Detection Screening Coverage Act; PAMA lab reporting delay included in HR 6363 Further Continuing Appropriations and other Extensions Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing; Use of real-world evidence in clinical trials and FDA review; Cancer Moonshot; FDA proposed regulation to provide oversight of diagnostic lab tests (FDA-2023-N-2177)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Providing an appropriate regulatory model for advanced genomic cancer testing (FDA-2023-2177)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on Oct. 20, 2023.
Original Filing: 301516109.xml
Lobbying Issues
Continue access to molecular and advanced genomic testing via telehealth; HR 2407/S The Medicare Multi-Cancer Early Detection Screening Coverage Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing; Use of real-world evidence in clinical trials and FDA review; Cancer Moonshot; FDA proposed regulation to provide oversight of diagnostic lab tests
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Providing an appropriate regulatory model for advanced genomic cancer testing
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on July 20, 2023.
Original Filing: 301491333.xml
Lobbying Issues
Continue access to molecular and advanced genomic testing via telehealth; HR 2407/S The Medicare Multi-Cancer Early Detection Screening Coverage Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing; Use of real-world evidence in clinical trials and FDA review; Cancer Moonshot, HR 3561 the PATIENT Act
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Providing an appropriate regulatory model for advanced genomic cancer testing
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on April 20, 2023.
Original Filing: 301464006.xml
Lobbying Issues
Continue access to molecular and advanced genomic testing via telehealth; The Multi-Cancer Early Detection Screening Coverage Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing; Use of real-world evidence in clinical trials and FDA review; Cancer Moonshot
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Providing an appropriate regulatory model for advanced genomic cancer testing
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on Jan. 20, 2023.
Original Filing: 301442534.xml
Lobbying Issues
Continue access to molecular and advanced genomic testing via telehealth; HR 8845, Multi-Cancer Early Detection Screening Coverage Act; HR 2617 Consolidated Appropriations Act of 2023
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing, The VALID Act HR 4128 and S 2209; Use of real-world evidence in clinical trials and FDA review. White House Cancer Moonshot Initiative; HR 2617 Consolidated Appropriations Act of 2023
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
The Valid Act and appropriate regulatory structure for advanced molecular and genomic testing, HR 2617 Consolidated Appropriations Act of 2023
Agencies Lobbied
U.S. Senate
Lobbying Issues
Strengthen the patent system for advanced molecular cancer diagnostic tests; S 4734 Patent Eligibility Restoration Act
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2022
In Q3, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on Oct. 20, 2022.
Original Filing: 301420004.xml
Lobbying Issues
Continue access to molecular and advanced genomic testing via telehealth; HR 8845, Multi-Cancer Early Detection Screening Coverage Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing, The VALID Act HR 4128 and S 2209; Use of real-world evidence in clinical trials and FDA review. White House Cancer Moonshot Initiative; HR 7667 the Food & Drug Administration Amendments of 2022; S 4348 the Food & Drug Administration Safety and Landmark Advancements Act of 2022
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
The Valid Act, HR 4128 and S 2209; HR 7667 the Food & Drug Administration Amendments of 2022; S 4348 the Food & Drug Administration Safety and Landmark Advancements Act of 2022
Agencies Lobbied
U.S. Senate
Lobbying Issues
Strengthen the patent system for advanced molecular cancer diagnostic tests; S 4734 Patent Eligibility Restoration Act
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2022
In Q2, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on July 20, 2022.
Original Filing: 301394887.xml
Lobbying Issues
Continue access to molecular and advanced genomic testing via telehealth; HR 8845, Multi-Cancer Early Detection Screening Coverage Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing, The VALID Act HR 4128 and S 2209; Use of real-world evidence in clinical trials and FDA review. White House Cancer Moonshot Initiative; HR 7667 the Food & Drug Administration Amendments of 2022; S 4348 the Food & Drug Administration Safety and Landmark Advancements Act of 2022
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
The Valid Act, HR 4128 and S 2209; HR 7667 the Food & Drug Administration Amendments of 2022; S 4348 the Food & Drug Administration Safety and Landmark Advancements Act of 2022
Agencies Lobbied
U.S. Senate
Lobbying Issues
Strengthen the patent system for advanced molecular cancer diagnostic tests
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2022
In Q1, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on April 20, 2022.
Original Filing: 301371982.xml
Lobbying Issues
Continue access to molecular and advanced genomic testing via telehealth; HR 8845, Multi-Cancer Early Detection Screening Coverage Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing, The VALID Act HR 4128 and S 2209; Use of real-world evidence in clinical trials and FDA review. Cancer Moonshot
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
The Valid Act, HR 4128 and S 2209
Agencies Lobbied
U.S. Senate
Lobbying Issues
Strengthen the patent system for advanced molecular cancer diagnostic tests
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2021
In Q4, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on Jan. 20, 2022.
Original Filing: 301336969.xml
Lobbying Issues
Continue access to molecular and advanced genomic testing via telehealth; HR 8845, Multi-Cancer Early Detection Screening Coverage Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing, The VALID Act HR 4128 and S 2209; Use of real-world evidence in clinical trials and FDA review.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
The Valid Act, HR 4128 and S 2209
Agencies Lobbied
U.S. Senate
Lobbying Issues
Strengthen the patent system for advanced molecular cancer diagnostic tests
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2021
In Q3, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on Oct. 20, 2021.
Original Filing: 301310835.xml
Lobbying Issues
Ensure the Protecting Access to Medicare Act (PAMA) continues to govern the provision of access to molecular and advanced genomic testing; Continue access to molecular and advanced genomic testing via telehealth
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing, The VALID Act HR 4128 and S 2209
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
The Valid Act, HR 4128 and S 2209
Agencies Lobbied
U.S. Senate
Lobbying Issues
Strengthen the patent system for advanced molecular cancer diagnostic tests
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2021
In Q2, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on July 20, 2021.
Original Filing: 301291706.xml
Lobbying Issues
Ensure the Protecting Access to Medicare Act (PAMA) continues to govern the provision of access to molecular and advanced genomic testing; Continue access to molecular and advanced genomic testing via telehealth
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Strengthen the patent system for advanced molecular cancer diagnostic tests
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2021
In Q1, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on April 20, 2021.
Original Filing: 301266989.xml
Lobbying Issues
Ensure the Protecting Access to Medicare Act (PAMA) continues to govern the provision of access to molecular and advanced genomic testing; Continue access to molecular and advanced genomic testing via telehealth; Preventing Across the Board Medicare Cuts, HR 1868
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
American Rescue Plan, HR 1319
Agencies Lobbied
U.S. Senate
Lobbying Issues
Strengthen the patent system for advanced molecular cancer diagnostic tests
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2020
In Q4, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on Jan. 20, 2021.
Original Filing: 301241900.xml
Lobbying Issues
Medicare coverage and reimbursement of Next Generation Sequencing and other advanced diagnostic testing for cancer.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA oversight of Next Generation Sequencing technology and other diagnostic tests for cancer. Medicare coverage of Next Generation Sequencing and other molecular diagnostic technology for cancer. VALID Act to provide FDA oversight of clinical laboratory testing. Section 8122 of SUPPORT for Patients and Communities Act to address application to cancer laboratories
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
VALID Act, discussion draft to provide Food & Drug Administration oversight of diagnostic laboratory testing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policy concepts to strengthen patent protections for cancer diagnostic tests
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2020
In Q3, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222808.xml
Lobbying Issues
Medicare coverage and reimbursement of Next Generation Sequencing and other advanced diagnostic testing for cancer.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA oversight of Next Generation Sequencing technology and other diagnostic tests for cancer. Medicare coverage of Next Generation Sequencing and other molecular diagnostic technology for cancer. VALID Act to provide FDA oversight of clinical laboratory testing. Section 8122 of SUPPORT for Patients and Communities Act to address application to cancer laboratories
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
VALID Act, discussion draft to provide Food & Drug Administration oversight of diagnostic laboratory testing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policy concepts to strengthen patent protections for cancer diagnostic tests
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2020
In Q2, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on July 20, 2020.
Original Filing: 301200190.xml
Lobbying Issues
Medicare coverage and reimbursement of Next Generation Sequencing and other advanced diagnostic testing for advanced cancers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA oversight of Next Generation Sequencing technology for advanced cancers. Medicare coverage of Next Generation Sequencing technology for advanced cancers. VALID Act to provide FDA oversight of clinical laboratory testing. Section 8122 of SUPPORT for Patients and Communities Act to address application to cancer laboratories
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
VALID Act, discussion draft to provide Food & Drug Administration oversight of diagnostic laboratory testing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policy concepts to strengthen patent protections for cancer diagnostic tests
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2020
In Q1, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on April 17, 2020.
Original Filing: 301171132.xml
Lobbying Issues
Medicare coverage and reimbursement of Next Generation Sequencing and other advanced diagnostic testing for advanced cancers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA oversight of Next Generation Sequencing technology for advanced cancers. Medicare coverage of Next Generation Sequencing technology for advanced cancers. VALID Act to provide FDA oversight of clinical laboratory testing. Section 8122 of SUPPORT for Patients and Communities Act to address application to cancer laboratories
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
VALID Act, discussion draft to provide Food & Drug Administration oversight of diagnostic laboratory testing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policy concepts to strengthen patent protections for cancer diagnostic tests
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2019
In Q4, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on Jan. 19, 2020.
Original Filing: 301121407.xml
Lobbying Issues
Medicare coverage and reimbursement of Next Generation Sequencing and other advanced diagnostic testing for advanced cancers. PAMA reform of clinical laboratory reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA oversight of Next Generation Sequencing technology for advanced cancers. Medicare coverage of Next Generation Sequencing technology for advanced cancers. PAMA reform of Medicare clinical laboratory payments. VALID Act to provide FDA oversight of clinical laboratory testing. Section 8122 of SUPPORT for Patients and Communities Act to address application to cancer laboratories
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
VALID Act, discussion draft to provide Food & Drug Administration oversight of diagnostic laboratory testing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tillis/Coons draft to strengthen patent protections for cancer diagnostic tests
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2019
In Q3, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on Oct. 21, 2019.
Original Filing: 301077543.xml
Lobbying Issues
Medicare coverage and reimbursement of Next Generation Sequencing and other advanced diagnostic testing for advanced cancers. PAMA reform of clinical laboratory reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA oversight of Next Generation Sequencing technology for advanced cancers. Medicare coverage of Next Generation Sequencing technology for advanced cancers. PAMA reform of Medicare clinical laboratory payments. VALID Act to provide FDA oversight of clinical laboratory testing. Section 8122 of SUPPORT for Patients and Communities Act to address application to cancer laboratories
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
VALID Act, discussion draft to provide Food & Drug Administration oversight of diagnostic laboratory testing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tillis/Coons draft to strengthen patent protections for cancer diagnostic tests
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2019
In Q2, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on July 22, 2019.
Original Filing: 301057328.xml
Lobbying Issues
Medicare coverage and reimbursement of Next Generation Sequencing and other advanced diagnostic testing for advanced cancers. PAMA reform of clinical laboratory reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA oversight of Next Generation Sequencing technology for advanced cancers. Medicare coverage of Next Generation Sequencing technology for advanced cancers. PAMA reform of Medicare clinical laboratory payments. VALID Act to provide FDA oversight of clinical laboratory testing. Section 8122 of SUPPORT for Patients and Communities Act to address application to cancer laboratories
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
VALID Act, discussion draft to provide Food & Drug Administration oversight of diagnostic laboratory testing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tillis/Coons draft to strengthen patent protections for cancer diagnostic tests
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2019
In Q1, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on April 22, 2019.
Original Filing: 301037099.xml
Lobbying Issues
Medicare coverage and reimbursement of Next Generation Sequencing and other advanced diagnostic testing for advanced cancers. PAMA reform of clinical laboratory reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA oversight of Next Generation Sequencing technology for advanced cancers. Medicare coverage of Next Generation Sequencing technology for advanced cancers. PAMA reform of Medicare clinical laboratory payments. VALID Act to provide FDA oversight of clinical laboratory testing.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
VALID Act, discussion draft to provide Food & Drug Administration oversight of diagnostic laboratory testing.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $20,000. The report was filed on Jan. 21, 2019.
Original Filing: 301012290.xml
Lobbying Issues
Medicare coverage and reimbursement of Next Generation Sequencing in advanced cancer. PAMA reform of clinical lab reimbursement
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA oversight of Next Generation Sequencing technology for advanced cancers. Medicare coverage of Next Generation Sequencing technology for advanced cancers. PAMA reform of Medicare clinical lab payments.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Discussion draft by Reps. Bucshon and DeGette to reform the Food & Drug Administration's oversight of diagnostic medical devices and clinical lab services.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $60,000. The report was filed on Oct. 22, 2018.
Original Filing: 300994996.xml
Lobbying Issues
Medicare coverage and reimbursement of Next Generation Sequencing in advanced cancer. PAMA reform of clinical lab reimbursement
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA oversight of Next Generation Sequencing technology for advanced cancers. Medicare coverage of Next Generation Sequencing technology for advanced cancers. PAMA reform of Medicare clinical lab payments.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Discussion draft by Reps. Bucshon and DeGette to reform the Food & Drug Administration's oversight of diagnostic medical devices and clinical lab services.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $60,000. The report was filed on July 18, 2018.
Original Filing: 300967571.xml
Lobbying Issues
Medicare coverage and reimbursement of Next Generation Sequencing in advanced cancer. Finalize PAMA reform of clinical lab reimbursement, date of service rules.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA oversight of Next Generation Sequencing technology for advanced cancers. Medicare coverage of Next Generation Sequencing technology for advanced cancers. Finalize PAMA reform of Medicare clinical lab payments.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Discussion draft by Reps. Bucshon and DeGette to reform the Food & Drug Administration's oversight of diagnostic medical devices and clinical lab services.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $60,000. The report was filed on April 20, 2018.
Original Filing: 300955049.xml
Lobbying Issues
Medicare coverage and reimbursement of Next Generation Sequencing in advanced cancer. Finalize PAMA reform of clinical lab reimbursement. Proposed National Coverage Decision on Next Generation Sequencing for cancer.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA oversight of Next Generation Sequencing technology for advanced cancers. Medicare coverage of Next Generation Sequencing technology for advanced cancers. Finalize PAMA reform of Medicare clinical lab payments.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Discussion draft by Reps. Bucshon and DeGette to reform the Food & Drug Administration's oversight of diagnostic medical devices and clinical lab services.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc , earning $40,000. The report was filed on Jan. 22, 2018.
Original Filing: 300937261.xml
Lobbying Issues
Medicare coverage and reimbursement of Next Generation Sequencing in advanced cancer. Finalize PAMA reform of clinical lab reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA oversight of Next Generation Sequencing technology for advanced cancers. Medicare coverage of Next Generation Sequencing technology for advanced cancers. Finalize PAMA reform of Medicare clinical lab payments.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2017
In Q3, SPLITOAK STRATEGIES LLC lobbied for Caris Science Inc . The report was filed on Jan. 31, 2018.
Original Filing: 300939350.xml
Lobbying Issues
Finalize PAMA clinical lab payment rates.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
SPLITOAK STRATEGIES LLC filed a lobbying registration on Oct. 31, 2017 to represent Caris Science Inc, effective Sept. 19, 2017.
Original Filing: 300918482.xml
Issue(s) they said they’d lobby about: Coverage and reimbursement of Next Generation Sequencing and other precision medicine technologies. Date of Service requirements, PAMA implementing regulations reforming clinical lab payment policy. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...